Current and relevant concepts in psoriatic arthritis

Revista Brasileira de Reumatologia

Volumn 52, Issue 1, 2012, Pages 92-106

  Goldenstein Schainberg, Claudia ^a   Favarato, Maria Helena Sampaio ^a   Ranza, Roberto ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Arthritis; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENTHESITIS; HYPERTENSION; IMMUNOGENETICS; LIFE EXPECTANCY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; HUMAN; REVIEW;

ARTHRITIS, PSORIATIC; HUMANS;

EID: 84856659684     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Goldenstein-Schainberg C, Saad CGS, Gonçalves CR. Espondiloartrites. In: Shinko SK (org.). Reumatologia. São Paulo: Editora Atheneu, 2010, p. 137-53.
2. Goldenstein-Schainberg C, Gonçalves CR. Artropatias soronegativas. In: Ricardo Fuller (org.). Manual de Reumatologia. v.1. São Paulo: Pontes Editores, 2007; p. 57-67.
3. Goldenstein-Schainberg C. Artrite psoriásica. In: Martins MA, Carilho FJ, Alves VAF, Castilho EA, Cerri GG, Wen CL (orgs.). Clínica Médica. v.5. Barueri: Manole, 2009; p. 628-31.
4. Goldenstein-Schainberg C, Gonçalves CR. Artrites soronegativas. In: Santo IS, Silva LBB, Lotufo PA, Benseñor IM (orgs.). Clínica Médica Diagnóstico e Tratamento. v.1. São Paulo: Sarvier, 2008; p. 92-101.
5. Meirelles ES, Gonçalves CR, Goldenstein-Schainberg C. Espondiloartropatias. In: Lopes AC, Neto VA, Chagas ACP, Zanini AC, Junior HS, Ferreira JFM et al. (orgs.). Tratado de Clínica Médica. 2.ed. v.1. São Paulo: Roca, 2009; p. 1590-8.
6. Lima FR, Gonçalves CR, Goldenstein-Schainberg C. Espondiloartropatias. In: Yoshinari NH, Bonfá ED (orgs.). Reumatologia para o Clínico. São Paulo: Roca, 2000; p. 111-22.
7. Bowcock AM. Understanding the pathogenesis of psoriasis, psoriatic arthritis and autoimmunity via a fusion of molecular genetics and immunology. Immunol Res 2005; 32:45-56.
8. Leung YY, Tam LS, Kun EW, Li EK. Psoriatic arthritis as a distinct disease entity. J Postgrad Med 2007; 53(1):63-71.
9. Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ et al. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010; 37(2):462-7.
10. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5(9):699-711.
11. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899-912.
12. Duffin KC, Chandran V, Gladman DD, Krueger GG, Elder JT, Rahman P. Genetics of Psoriasis and Psoriatic Arthritis: Update and Future Direction. J Rheumatol 2008; 35:1449-53.
13. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199-204.
14. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13:R43-55.
15. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005; 152:1098-107.
16. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauveit A. Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines. Curr Rheumatol Rep 2007; 9:461-7.
17. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54(8):2665-73.
18. Helliwell PS, GRAPPA Group. GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, Stockholm, May/ June 2006. J Rheumatol 2007; 34(1):214-9.
19. McGonagle D, Lyn TA. Are the classification criteria for psoriatic arthritis better than existing criteria for diagnosing psoriatic arthritis? Comment on the article by Taylor et al. Arthritis Rheum 2007; 56(2):699-700.
20. Van den Bosch F, Cryssen BV, Mielants H. Clinical assessment in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006; 18(4):354-8.
21. Fitzgerald O, Dougados M. Psoriatic arthritis: one or more diseases? Best Pract Res Clin Rheumatol 2006; 20(3):435-50.
22. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3(1):55-78.
23. Mease P. Psoriatic arthritis update. Bull Hosp Jt Dis 2006; 64:25-31.
24. Favarato MH, Saad CG, Gonçalves CR, Sampaio-Barros PD, Goldensteins-Schainberg C. Hypertension and diabetes significantly enhance the risk for cardiovascular disease in patients with psoriatic arthritis. Arthritis Rheum 2010; 62:S221.
25. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13(3):586-92.
26. Chandran V, Gladman DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010; 12(4):288-94.
27. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol 2010; 39(4):299-302.
28. Tan AL, Benjamin M, Toumi H, Grainer AJ, Tanner SF, Emery P et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis - a high-resolution MRI and histological study. Rheumatology 2007; 46(2):253-6.
29. Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol 2010; 49:901-6.
30. Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L et al. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010; 37(2):453-61.
31. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis 2006; 65(Suppl 3):iii22-24.
32. Dominguez P, Gladman DD, Helliwell P, Mease PJ, Husni ME, Qureshi AA. Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep 2010; 12(4):295-9.
33. Gladman DD, Mease PJ, Choy EH, Richtlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010; 12(3):R113.
34. Kane D, Fitzgerald O. Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep 2004; 6(4):292-8.
35. Coates LC, McGonagle DM, Hodgson R, Gisondi P, Kavanaugh AF, Qureshi AA et al. Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010; 37(2):448-52.
36. de Miguel E, Cobo T, Muñoz-Fernández S, Naredo E, Usón J, Acebes JC et al. Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 2009; 68(2):169-74.
37. DelleSedie A, Riente L, Filippucci E, Scirè CA, Iagnocco A, Gutierrez M et al. Ultrasound imaging for the rheumatologist XXVI. Sonographic assessment of the knee in patients with psoriatic arthritis. Clin Exp Rheumatology 2010; 28(2):147-52.
38. Coates LC, Anderson RR, Fitzgerald O, Gottlieb AB, Kelly SG, Lubrano E et al. Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: A literature review. J Rheumatol 2008; 35(7):1438-42.
39. Gutierrez M, Filippucci E, De Angelis R, Filosa G, Kane D, Grassi W. A sonographic spectrum of psoriatic arthritis: "the five targets". Clin Rheumatol 2010; 29(2):133-42.
40. Gutierrez M, Filippucci E, Bertolazzi C, Grassi W. Sonographic monitoring of psoriatic plaque. J Rheumatol 2009; 36:850-1.
41. Helliwell PS, Porter G, Taylor WJ; The CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis 2007; 66(1):113-7.
42. Stamm TA, Nell V, Mathis M, Coenen M, Aletaha D, Cieza A et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007; 57(3):487-94.
43. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013-20.
44. Mumtaz A, Fitzgerald O. Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice. Curr Rheumatol Rep 2010; 12(4):264-71.
45. Gottlieb AB, Dann F. Comorbidities in Patients with Psoriasis. Am J Med 2009; 122(12):1150.e1-9.
46. Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, Oshea D et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37:1386-94.
47. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68(7):1131-5.
48. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40:1868-72.
49. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11:229.
50. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26:S62-S65.
51. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Sem Arthritis Rheum 2004; 34:585-92.
52. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P. Boehncke WH et al.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68(9):1387-94.
53. Mease PJ. Psoriatic Arthritis: Pharmacotherapy Update. Curr Rheumatol Rep 2010 May 20. [Epub ahead of print] PMID: 20490726.
54. Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006; 33(7):1417-21.
55. Griffiths CE. Therapy for Psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheum 1997; 36:409-12.
56. Menter A, Gottlieb A, Feldman SR, Voorhees AS, Leonardi CL, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1- Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826-50.
57. Mahajan A, Tandon VR. Corticosteroids in Rheimatology: Friends or foes. JIACM 2005; 6:275-80.
58. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulfors MI. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. J Am Acad Dermatol 1998; 38:318-21.
59. Goldenstein-Schainberg C, Titton DC, Lima FAC, Pinheiro GRC, Novaes GS, Bértolo MB. Segurança com uso de Anti-TNF. V.1. São Paulo: Editora de Projetos Médicos, 2007; p. 50.
60. Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006; 24(5):587-93.
61. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869-76.
62. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory PA et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-72.
63. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56:476-88.
64. Kavanaugh A, McInnes I, Mease P, Krueger GC, Gladman D, Gomez-Reino J et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in Psoriatic Arthitis: 24-week efficacy and safety results of a randomized placebo-controlled study. Arthitis Rheum 2009; 60:976-86.
65. Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. BioDrugs 2009; 23:125-35.
66. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R et al. The assessment of Spondyloarthitis international Society (ASAS) handbook: a guide to Access spondyloarthitis. Ann Rheum Dis 2009; 68:ii1-44.
67. Sampaio-Barros P, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SC, Carvalho MA et al. Consenso brasileiro de espondiloartropatias: Espondilite anquilosante e artrite psoriásica - Diagnóstico e tratamento - Primeira Revisão. Rev Bras Reumatol 2007; 47(4):234-51.
68. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata - First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1-14.
69. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-40.
70. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46(10):2776-84.